Literature DB >> 21970932

Total hip arthroplasty and bone fragility.

Paolo Cherubino1, Chiara Ratti, Alessandro Fagetti, Tommaso Binda.   

Abstract

The number of elderly people is steadily increasing: in the United States it will increase from 12.9% to 20% in 2030 with respect to the total population. Italy, with UK, Denmark and Sweden are the countries with the largest number of octogenarians (about 4% of the population) and it is estimated that this rate will increase by 300% over the next 50 years. The number of people affected by osteoarthritis will increase significantly and therefore the number of total hip arthroplasties will progressively increase. The success of an implant depends firstly by a flawless surgical technique, a correct and stable implant fixation and an optimal preoperative planning that should consider the bone quality of the patient, in order to choose a proper implant design. Different approaches could be followed to achieve adequate fixation: northern Europe surgeons prefer the cemented implant, instead American orthopedics generally use systems that allow a direct biological osteointegration. Elderly patients often present with multiple local and general problems that could affect significantly the normal course of a prosthetic surgery procedure and its results: they have bone tissue changes that lead to increased bone fragility and, consequently, difficulties to obtain primary stability. Osteoporotic bone is characterized by reduction of bone mass, decrease of cancellous bone trabeculae and by increased porosity of cortical bone. The bone fragility implies a greater risk of iatrogenic intraoperative fractures. Furthermore, difficulties linked to bone stock deficiencies become even more significant in revision surgery, where cortical bone thinning is associated with enlargement of the isthmus thus making more difficult to obtain distal fixation of prosthetic stems. At the moment, the role played by the drugs used for the treatment of osteoporosis during implant osteointegration is still not clearly understood and is still under investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21970932

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  6 in total

Review 1.  Concise review: the periosteum: tapping into a reservoir of clinically useful progenitor cells.

Authors:  Hana Chang; Melissa L Knothe Tate
Journal:  Stem Cells Transl Med       Date:  2012-05-30       Impact factor: 6.940

2.  [Revised consensus classification. Histopathological classification of diseases associated with joint endoprostheses].

Authors:  V Krenn; L Morawietz; H Kienapfel; R Ascherl; G Matziolis; J Hassenpflug; M Thomsen; P Thomas; M Huber; C Schuh; D Kendoff; D Baumhoer; M G Krukemeyer; G Perino; J Zustin; I Berger; W Rüther; C Poremba; T Gehrke
Journal:  Z Rheumatol       Date:  2013-05       Impact factor: 1.372

Review 3.  [The spectrum of histomorphological findings related to joint endoprosthetics].

Authors:  L Morawietz; V Krenn
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

4.  Single-dose local simvastatin injection improves implant fixation via increased angiogenesis and bone formation in an ovariectomized rat model.

Authors:  Jie Tan; Ning Yang; Xin Fu; Yueyi Cui; Qi Guo; Teng Ma; Xiaoxue Yin; Huijie Leng; Chunli Song
Journal:  Med Sci Monit       Date:  2015-05-18

5.  A novel hierarchical biofunctionalized 3D-printed porous Ti6Al4V scaffold with enhanced osteoporotic osseointegration through osteoimmunomodulation.

Authors:  Wei Wang; Yinze Xiong; Renliang Zhao; Xiang Li; Weitao Jia
Journal:  J Nanobiotechnology       Date:  2022-02-05       Impact factor: 10.435

6.  Comorbid diseases as predictors of survival of primary total hip and knee replacements: a nationwide register-based study of 96 754 operations on patients with primary osteoarthritis.

Authors:  Esa Jämsen; Mikko Peltola; Antti Eskelinen; Matti U K Lehto
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.